Lupvindol Biosciences is a UK-headquartered, clinical-stage biopharmaceutical company developing patented fixed-dose therapies that pair corticosteroids with cannabidiol to treat inflammatory and autoimmune conditions in animals and, eventually, people. Its veterinary-first program has opened FDA investigational files for canine inflammatory bowel disease and equine osteoarthritis, while its research explores reducing steroid exposure without losing anti-inflammatory effect. The company brings together expertise in cannabinoid development, pharmacology, veterinary medicine, and pharmaceutical regulation.
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA
MesaGreen Pharmaceutical CompanyMesaGreen Pharmaceutical Company is a virtual animal-health pharmaceutical developer creating an at-home emergency treatment for breakthrough seizures in dogs. The Frederick company is developing its K9MGP product around an auto-injection system intended to deliver rapid rescue therapy, drawing on human drug-delivery experience and veterinary research. MesaGreen is a small veteran-owned business and a wholly owned subsidiary of Mesa Science Associates.FREDERICK, MD
GSK plcGSK plc is a focused biopharmaceutical company that discovers, develops and delivers medicines and vaccines. Its research and development concentrates on respiratory, immunology and inflammation; oncology; HIV; and infectious diseases, with R&D hubs in the UK, US and Belgium and a network spanning Europe, North America and Asia.PENNSYLVANIA, PA